Prism Medico and Pharmacy Limited has submitted the scrutinizer's report for its Extraordinary General Meeting held on March 20, 2026, revealing overwhelming shareholder support with 99.98% approval for both special business resolutions. The company formally communicated the voting outcomes to BSE Limited and Metropolitan Stock Exchange of India Limited on March 24, 2026, completing the regulatory compliance process under Section 108 of the Companies Act, 2013.

EGM Proceedings and Shareholder Participation

The company's EGM was successfully conducted on March 20, 2026, at 01:00 P.M. through Video Conferencing/Other Audio Visual Means, chaired by Mrs. Sakshi Laller, Wholetime Director. The meeting concluded at 01:17 P.M. after addressing key corporate governance matters under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Voting Results and Scrutinizer's Report

M/s. M.R. Chechi & Associates, Practicing Company Secretaries from Chandigarh, served as scrutinizers for the e-voting process. CS Mast Ram Chechi (M. No.: 3823/C.P. No.: 2906) prepared the consolidated scrutinizer's report dated March 24, 2026, revealing exceptional shareholder consensus.

E-Voting Process and Participation

The company partnered with National Securities Depositories Limited (NSDL) to provide comprehensive voting facilities through their platform at www.evoting.nsdl.com . Remote e-voting commenced at 9:00 A.M. on March 17, 2026, and concluded at 5:00 P.M. on March 19, 2026. A total of 43 voters participated in the consolidated voting process across both remote e-voting and live e-voting during the meeting.

Regulatory Compliance and Communication

Director Davender Singh (DIN: 09447213) formally submitted the scrutinizer's report to both stock exchanges on March 24, 2026. The electronic voting details were downloaded from the NSDL Portal and votes were unblocked at 02:09 P.M. on March 20, 2026, after the EGM conclusion, in the presence of two independent witnesses - Tanish and Sparsh.

Preferential Issue Utilization Plan

With the approval of the preferential issue resolution, the company can now proceed with its comprehensive utilization plan for ₹25.00 crore:

The successful completion of the EGM and overwhelming shareholder approval enables Prism Medico to proceed with its pharmaceutical manufacturing expansion and corporate restructuring initiatives from its registered office at Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030.

Prism Medico & Pharmacy Limited announced significant corporate developments following its board meeting held on February 23, 2026. The board approved a comprehensive fundraising plan and key amendments to facilitate future capital raising activities.

Board Meeting Outcomes

The board meeting, which commenced at 01:00 P.M. and concluded at 06:30 P.M. on February 23, 2026, resulted in several important approvals. The directors considered and approved the alteration of Article 15 of the Articles of Association by inserting a new clause to empower the company to issue further securities through various methods including preferential offers or private placements.

The board also approved the issuance of securities to both promoter and non-promoter categories, subject to shareholder approval at the upcoming Extraordinary General Meeting.

Securities Issuance Details

The issue price of Rs. 20 per equity share and convertible warrant has been calculated in accordance with SEBI ICDR Regulations and is not lower than the floor price determined under Regulation 164 read with 166A of Chapter V of SEBI ICDR Regulations.

Convertible Warrants Structure

The convertible warrants carry specific terms for conversion and payment. Minimum 25% of the warrant price would be payable upfront at the time of application, while the balance 75% shall be payable at the time of conversion into equity shares.

Key warrant features include:

• Conversion Ratio: 1:1 (each warrant converts to one equity share)
• Conversion Period: 18 months from allotment date
• Flexibility: Conversion possible in one or more tranches
• Lapse Condition: Warrants lapse if not exercised within stipulated period

Investor Allocation

The allocation includes seven specific investors, with Symbiosis Pharmaceuticals Private Limited and Galaxy Vitacare Private Limited representing the promoter category. The non-promoter category comprises five investors including Sejal S Nashatar, Harsh Jentibhai Rupareliya, Shilpa Harsh Rupareliya, Raju Tyagi, and Dharmender Kharb.

Extraordinary General Meeting

The board approved convening an Extraordinary General Meeting of members on Friday, March 20, 2026, through Video Conferencing and Other Audio-Visual Means as per relevant MCA and SEBI circulars. The EGM will seek shareholders' approval for the proposed securities issuance and Articles of Association amendments.

Mr. Mast Ram Chechi, proprietor of M/s. M.R. Chechi and Associates, Practicing Company Secretaries, has been appointed as Scrutinizer to oversee the e-voting process in a fair and transparent manner.

Shareholding Impact

Post-allotment, the total number of investors will increase significantly, with the promoter holding expected to change from the current 22.61% to 74.72% of the expanded share capital. The preferential issue represents a substantial expansion of the company's equity base and provides significant capital for future growth initiatives.